TORONTO, Sept. 27 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today
announced the co-sponsorship with Toray Medical Company (Tokyo, Japan) of a
key scientific session at SEPSIS 2007, an International Symposium held at the
Institut Pasteur in Paris, France from September 26-29th, 2007. "Endotoxemia -
Detection, Consequence and Intervention" will feature a panel of four thought
leaders in the field of sepsis discussing the value of Spectral's EAA(TM)
Endotoxin Activity Assay. The EAA(TM) is the only FDA cleared, whole blood
assay for the detection of endotoxemia.
"There is growing recognition of the role that exdotoxins play in the
onset of Sepsis, as is reflected by the number of sessions at this symposium
that will address this topic," said Dr. Paul Walker, President and CEO of
Spectral Diagnostics. "We are pleased to participate in SEPSIS 2007 as it
gives us the opportunity to further demonstrate the utility of our EAA(TM)
Endotoxin Activity Assay to a large group of clinicians who are focused on
treating patients with Sepsis."
The "Endotoxemia - Detection, Consequence and Intervention" scientific
session will take place on Friday, September 28, 2007 at the Institut Pasteur
Auditorium at 16:30CEST and the panel will include International Sepsis Forum
Chair, Dr. John Marshall of St. Michael's Hospital in Toronto, Canada. For
further information please visit: http://www.sepsisforum.org.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral technologies provide accurate and timely
information to clinicians enabling the early initiation of appropriate and
targeted therapy. Current products include Spectral's FDA approved rapid
diagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid
diagnostic for sepsis (EAA(TM)), as well as a range of other biological
reagents. Spectral is listed on TSX under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
For further information:
For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; James Smith, Investor Relations, (416) 815-0700 ext. 229,